Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARDN.L Regulatory News (ARDN)

  • There is currently no data for ARDN

Trading Update

1 May 2020 07:00

RNS Number : 5287L
Arden Partners plc
01 May 2020
 

Arden Partners plc

("Arden" or the "Company")

 

Trading Update

 

Arden is today issuing a trading update in respect of the six-month period ended 30 April 2020.

 

Arden made a good start to the six-month trading period despite it encompassing the elevated political uncertainty around Brexit and then the General Election. Trading towards the end of the period has been impacted by the significant global market declines in reaction to the COVID-19 pandemic.

 

Compared to the performance in the six months ended 30 April 2019, we anticipate materially higher corporate finance revenues, higher retainer levels but lower equity commissions. The equity trading operation suffered material losses as markets fell in response to COVID-19.

 

The Board has implemented steps to reduce the Company's cost base. As a result, the Company's current annual cost base is anticipated to be more than 25% lower than last year. The measures taken include salary and fee sacrifices for all Board members and certain senior employees of in excess of 40% of salary; salary sacrifices for all other employees; the furloughing of a number of staff and the cancellation or deferral of all discretionary expenditure. Arden will also defer the payment of VAT in line with the government's proposals. The Board will continue to take action to reduce costs and minimise the financial impact of the uncertainty caused by COVID 19.  

 

Before taking into account the equity trading book losses, Arden expects to report a profit for the six-month period. After taking into account the equity trading book losses, Arden expects to report a reduced loss for the period compared to the prior year.

 

The Company has a strong balance sheet, with cash and cash equivalent resources well in excess of its regulatory requirements.   

 

Operationally, we responded to COVID-19 promptly and successfully implemented a comprehensive remote working capability, which has enabled us to ensure both the wellbeing of our staff and the ability to continue servicing our clients as normal. The Company is fully operational and continues to operate as normal. Due to the quality and flexibility of our people and the strengths of our business, our ability to attract and win new high-quality corporate clients remains strong. We continue to sign up quality clients and have a good pipeline going forward.

 

We are working closely with our corporate clients to assess the disruption caused by COVID-19 and, where possible, assist them in protecting their businesses and continuing to implement their strategies. Our aim is to fully support all corporate and institutional clients during these unprecedented times.

 

Mark Ansell, Chairman, commented:

 

"The COVID-19 crisis has presented unprecedented challenges to our business. However, it remains in a strong financial position and we have taken the necessary actions to enable us to confront the current market environment without harming our ability to fully service our clients. The Board is indebted to the Company's employees for their hard work and ongoing support in light of these challenges.

 

The Board's priorities remain to protect the Company's balance sheet and to deliver on our stated growth strategy."

 

 

For further information, please contact:

 

Arden Partners plc

 

020 7614 5900

Donald Brown - Chief Executive Officer

James Reed-Daunter - Executive Director

Steve Douglas - Group Finance Director

 

GCA Altium Limited (NOMAD)

 

020 7484 4040

Tim Richardson

 

 

Notes for editors:

 

Arden is a dedicated corporate adviser and multi-service stockbroker to small and mid-cap companies in the UK and their investors.

 

The absolute core of our business is the effective management of the needs of our significant and growing base of corporate clients, and the effective support of their relationships with existing and potential shareholders. 

 

These relationships are enhanced by the quality of our corporate finance advice and industry research, and the strong market presence of our sales and trading teams.

 

Our corporate finance capabilities encompass M&A, corporate finance advisory, broking and Sponsor and NOMAD services. We represent our clients in private transactions and AIM and Main Market share issues.

 

Our research is designed to be sector focused, concentrating on top down thematic trends which highlight companies giving investors an exposure to the real growth areas of the small-cap and AIM markets.

 

It is the job of the sales team to keep institutions abreast of these themes and stock ideas. When there is a requirement for our corporate clients to raise money to fulfil their growth ambitions, the sales team is in a strong position to effect this, with its entrenched relationships with the UK institutional and non-institutional markets.

 

Our market making and trading teams provide liquidity in the shares of our corporate clients. We also trade the shares of non-client corporates on behalf of institutions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKKBNBBKDQQN
Date   Source Headline
10th Nov 20104:10 pmRNSTransaction in own shares and Total Voting Rights
10th Nov 20102:56 pmRNSHolding(s) in Company
8th Nov 20101:33 pmRNSHolding(s) in Company
8th Nov 20101:06 pmRNSTransaction in own shares and Total Voting Rights
5th Nov 201010:33 amRNSTransaction in own shares and Total Voting Rights
2nd Nov 20107:00 amRNSTrading update
19th Oct 201010:39 amRNSForm 8.5 (EPT/NON-RI)
18th Oct 201011:03 amRNSForm 8.5 (EPT/NON-RI)
15th Oct 201010:49 amRNSForm 8.5 (EPT/NON-RI)
13th Oct 201011:34 amRNSForm 8.5 (EPT/NON-RI)
8th Oct 201011:08 amRNSForm 8.5 (EPT/NON-RI)
7th Oct 201011:25 amRNSForm 8.5 (EPT/NON-RI)
6th Oct 201012:33 pmRNSBoard change
6th Oct 201011:25 amRNSForm 8.5 (EPT/NON-RI)
1st Oct 201010:14 amRNSForm 8.5 (EPT/NON-RI)
30th Sep 201011:23 amRNSForm 8.5 (EPT/NON-RI)
28th Sep 20104:59 pmRNSForm 8.5 (EPT/NON-RI) - Amendment
28th Sep 201010:56 amRNSForm 8.5 (EPT/NON-RI)
27th Sep 201011:28 amRNSForm 8.5 (EPT/NON-RI)
24th Sep 20103:36 pmRNSForm 8.5 (EPT/NON-RI)
10th Sep 20107:00 amRNSTrading update and Director's declaration
12th Jul 20109:58 amRNSForm 8.5 (EPT/NON-RI)
8th Jul 201010:16 amRNSForm 8.5 (EPT/NON-RI)
8th Jul 201010:14 amRNSForm 8.5 (EPT/NON-RI)
30th Jun 201010:25 amRNSForm 8.5 (EPT/NON-RI)
29th Jun 201011:26 amRNSForm 8.5 (EPT/NON-RI)
28th Jun 201010:19 amRNSForm 8.5 (EPT/NON-RI)
22nd Jun 20107:00 amRNSBoard Changes
22nd Jun 20107:00 amRNSInterim results for the six months ended 30 April
16th Jun 20109:19 amRNSExtel 2010
10th Jun 20109:36 amRNSForm 8.5 (EPT/NON-RI)
24th May 201011:30 amRNSForm 8.5 (EPT/NON-RI)
21st May 201012:09 pmRNSBlocklisting Return
11th May 201011:14 amRNSForm 8.5 (EPT/NON-RI)
10th May 201010:35 amRNSForm 8.5 (EPT/NON-RI)
7th May 201010:27 amRNSForm 8.5 (EPT/NON-RI)
6th May 20109:37 amRNSForm 8.5 (EPT/NON-RI)
5th May 201010:12 amRNSForm 8.5 (EPT/NON-RI)
4th May 201010:30 amRNSForm 8.5 (EPT/NON-RI)
26th Mar 20104:14 pmRNSDirector's dealing
25th Mar 20102:16 pmRNSResult of AGM
25th Mar 20107:00 amRNSAGM Statement
10th Mar 20102:55 pmRNSHolding(s) in Company
2nd Mar 201012:58 pmRNSAnnual Financial Report
1st Mar 201010:47 amRNSTotal Voting Rights
12th Feb 201012:19 pmRNSDirectors' dealings
2nd Feb 201011:20 amRNSEPT Disclosure
29th Jan 201011:21 amRNSEPT Disclosure
28th Jan 20107:00 amRNSPreliminary results for the year ended 31 October
25th Jan 201011:41 amRNSEPT Disclosure - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.